Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Capital Expenditures: 2013-2023

Historic Capital Expenditures for Zevra Therapeutics (ZVRA) over the last 11 years, with Dec 2023 value amounting to $296,000.

  • Zevra Therapeutics' Capital Expenditures was N/A to $554,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $938,000, marking a year-over-year change of. This contributed to the annual value of $296,000 for FY2023, which is 218.28% up from last year.
  • According to the latest figures from FY2023, Zevra Therapeutics' Capital Expenditures is $296,000, which was up 218.28% from $93,000 recorded in FY2022.
  • In the past 5 years, Zevra Therapeutics' Capital Expenditures registered a high of $296,000 during FY2023, and its lowest value of $26,000 during FY2019.
  • For the 3-year period, Zevra Therapeutics' Capital Expenditures averaged around $163,667, with its median value being $102,000 (2021).
  • As far as peak fluctuations go, Zevra Therapeutics' Capital Expenditures declined by 8.82% in 2022, and later skyrocketed by 218.28% in 2023.
  • Zevra Therapeutics' Capital Expenditures (Yearly) stood at $26,000 in 2019, then rose by 26.92% to $33,000 in 2020, then soared by 209.09% to $102,000 in 2021, then dropped by 8.82% to $93,000 in 2022, then surged by 218.28% to $296,000 in 2023.